Ian Novick completed the IRONMAN® Cozumel! Time 10:59:35, Run 04:55:25. (UNOFFICIAL) track.rtrt.me/e/IRM-COZUMEL-… #IMCozumel
1
1
Ian Novick completed Bike. Time 04:58:08. track.rtrt.me/e/IRM-COZUMEL-… #IMCozumel
1
Ian Novick completed Swim. Time 00:57:01. track.rtrt.me/e/IRM-COZUMEL-… #IMCozumel
1
Ian Novick started the IRONMAN® Cozumel! track.rtrt.me/e/IRM-COZUMEL-… #IMCozumel
1
Our team just applied to Startup World Cup @SWC2022 #innovacell #StartupWorldCup
2
DiscGenics teams up with Tokai U. to commence dosing in their JPN trial for back pain #regenerativemedicine #DiscGenics #IDCT #Tokai #Nikkei #日経 #DDD #BackPain #celltherapy #conditionalapproval
r.nikkei.com/article/DGXMZO4…
Colin Lee Novick retweeted
Replying to @cnovick1981
@cnovick1981 also featured a great article in the latest AusBiotech Journal: ow.ly/d/6WPx
Apparently my account was hacked by a rather risque (and probably illegal) service provider. Apologies for the inconvenience.
1
A fun little article that sites findings in the Tufts CSDD Impact Report for Regenerative Medicine
lnkd.in/e2CRSnv
1
Ono Pharmaceutical licenses Celyad's allogeneic NKR-2 immunotherapy for upfront payment of 1.25b JPY! More Japan!!
lnkd.in/dFpCuuE
#sunset at #yokosuka Stn. I never knew that the support rails were from the #meijiera (1868 -… instagram.com/p/BHrZpu-h--m/ – at Yokosuka-shi, Kanagawa
1
Takenaka Corporation opened a new Bio Research Center that has a RegenMed CPC for biotechs looking to advance R&D!
lnkd.in/edApe7e
1
Takeda Pharmaceuticals and TiGenix enter Ex-US Licensing Agreement for Cx601 with 25mEUR upfront payment!
lnkd.in/enyDpxa
Sosei launches an 8yr, 2 billion JPY fund called "RMF1" for investment into Japanese regenerative medicine firms
lnkd.in/e2nWNde
2
Adv Ctr for Tissue Eng (ACTE) to provide Daiichi Sankyo, with dental pulp cells and conduct collaborative research
lnkd.in/er6RCGe
Japan's MHLW to ease the number of steps needed for starting recombinant microorganism (or virus) clinical trials
lnkd.in/eKEi_cY
A brief yet informative piece on the question "why Japan?" for pharmaceutical development by PAREXEL.
lnkd.in/eidFqcR
Cytori OA cell therapy approved under Japan's ASRM (not PMD Act conditional approval as article title suggests)
lnkd.in/eSNURKT
TEMCELL used in 16 patients since release in FEB 2016. That's circa 216m JPY (2m USD) in sales in 4~5 mths.
lnkd.in/dpgwjN7
RepliCel's (and Shiseido's) RCH-01 treatment or androgenic alopecia (AGA) featured in a Weekly Diamond article!
lnkd.in/eN_ZmY7


